Wyden Statement on Trump Announcement of Medicare-Negotiated Drug Prices
Washington, D.C. — Senate Finance Committee Ranking Member Ron Wyden, D-Ore., today issued the following statement after the Trump administration announced the next round of Medicare-negotiated prices on 15 of the most expensive prescription drugs in Medicare.
“Democrats took on Big Pharma by giving Medicare the power to negotiate on behalf of the tens of millions of seniors that want lower drug prices while every Republican voted against it,” Wyden said. “Today’s announcement is a result of that effort by Democrats to lower health costs for older Americans. Medicare drug price negotiation is about to deliver tangible lower costs to seniors in Medicare, unlike Trump’s ceremonial events with Big Pharma CEOs in the Oval Office. Republicans neutered future Medicare drug price negotiations by adding delays and exemptions to some of the most expensive drugs, especially cancer drugs like Keytruda.”
Last week, Wyden led a call for Trump to release the latest round of Medicare-negotiated drug prices. Wyden also led efforts to repeal the provision in Trumpcare that gives Big Pharma a windfall by delaying or exempting certain blockbuster drugs from Medicare negotiation.
###
Previous Article